Martin Menter
Dermatology · Dallas, TXNPI 1043268907
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $349,619 of the $511,603 with a category attached, or 68.3%. It is spread thinly across 34 manufacturers, the largest accounting for just 18.7%. Reporting peaked in 2019 at $275,846 and has fallen 100.0% since, to $36 in 2023. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 834 payments — averaging $613.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$96K
- Lilly USA, LLC$95K
- AbbVie$91K
- Sun Pharmaceutical Industries Inc.$54K
- Amgen$29K
- UCB, Inc.$23K
- plus $124K from 28 others
Across 415 payments — averaging $7670.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$882K
- Boehringer Ingelheim$586K
- UCB SA$539K
- Janssen Research & Development, LLC$494K
- Novartis$217K
- E.r. Squibb & Sons, L.L.C.$113K
- plus $352K from 12 others
What the payments were for
- Consulting fees$109,23221%
- Speaking & faculty fees$349,61968%
- Travel & lodging$36,1287%
- Food & beverage$16,2203%
- Education$1410%
- Gifts$2640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 58 | $95,750 |
| Lilly USA, LLC | 128 | $95,466 |
| AbbVie(2 entities) | 141 | $90,909 |
| Sun Pharmaceutical Industries Inc. | 73 | $53,635 |
| Amgen | 44 | $29,005 |
| UCB, Inc. | 29 | $22,637 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 42 | $21,704 |
| Eli Lilly | 5 | $19,775 |
| Bristol Myers Squibb | 31 | $19,038 |
| Novartis | 86 | $17,030 |
| Johnson & Johnson | 70 | $15,971 |
| Boehringer Ingelheim | 5 | $8,518 |
| Mindera Corp | 3 | $6,825 |
| Zerigo Health, Inc. | 5 | $5,304 |
| UCB SA | 2 | $4,000 |
| Mayne Pharma Commercial LLC | 34 | $3,220 |
| E.r. Squibb & Sons, L.L.C. | 4 | $1,267 |
| LEO Pharma Inc. | 18 | $474 |
| Regeneron Healthcare Solutions, Inc. | 11 | $242 |
| Sanofi | 8 | $156 |
| Incyte Corporation | 2 | $139 |
| Encore Dermatology Inc. | 6 | $108 |
| Pfizer | 6 | $104 |
| EPI Health, LLC | 4 | $67 |
| Merck | 6 | $46 |
| DUSA Pharmaceuticals, Inc. | 2 | $40 |
| Biofrontera Inc. | 2 | $37 |
| Genentech USA, Inc. | 2 | $28 |
| Tactile Systems Technology Inc | 2 | $28 |
| Oxford Immunotec USA Inc | 1 | $20 |
| Medexus Pharma, Inc. | 1 | $20 |
| Promius Pharma LLC | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $13 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$511,603 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Other dermatology in Dallas
- Jennifer CatherDallas$1.3M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- So Yeon PaekDallas$812K
- Mary HornerDallas$448K
- Donald GlassDallas$347K
- William AbramovitsDallas$325K
- Mary FleischliDallas$153K
- Adean KingstonDallas$141K
- Edward LainAustin$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.